SEATTLE--(BUSINESS WIRE)--According to Coherent Market Insights, the North America & Europe age-related macular degeneration therapeutics market is estimated to be valued at US$ 9,958.7 million in 2020 and is expected to exhibit a CAGR of 6.1% during the forecast period (2020-2027).
Key Trends and Analysis of the North America & Europe Age-related Macular Degeneration Therapeutics Market:
Key trends in the market are the increasing prevalence of age-related macular degeneration, the increasing number of approvals and launches of therapeutics for treatment of age-related macular degeneration, and strategic acquisitions, partnerships, and agreements by key players. These factors are expected to aid growth of the market.
According to the American Academy of Ophthalmology 2020, the prevalence of age-related macular degeneration in the U.S. is roughly 85–90% dry age-related macular degeneration and 10–15% wet age-related macular degeneration.
Moreover, the increasing number of approvals and launches of age-related macular degeneration therapeutics is expected to drive the market growth during the forecast period. For instance, Regeneron Pharmaceuticals, Inc. announced that the U.S. Food and Drug Administration (FDA) approved the Chemistry, Manufacturing and Controls (CMC) Prior-Approval Supplement (PAS) for the EYLEA (aflibercept) Injection prefilled syringe.
Furthermore, adoption of strategic acquisitions by key players is expected to propel the market growth during the forecast period. For instance, in February 2020, Gemini Therapeutics and Singapore Eye Research Institute (SERI) entered a research collaboration to expand, explore, and discover new targets for treatment of age-related macular degeneration.
Request Sample Copy of this Report @ https://www.coherentmarketinsights.com/insight/request-sample/4171
Key Market Takeaways:
The North America & Europe age-related macular degeneration therapeutics market is expected to exhibit a CAGR of 10.2% during the forecast period owing to launches of age-related macular degeneration therapeutics by market players. For instance, in October 2019, Bausch + Lomb, a subsidiary of Bausch Health Companies Inc., launched PreserVision AREDS 2 Formula mini gel eye vitamins for people with moderate to advanced age-related macular degeneration (AMD) in the U.S.
Among regions, North America is expected to hold dominant position in the market during the forecast period owing to high presence of key players such as Novartis AG, and the increasing prevalence of age-related macular degeneration. According to FIGHTING BLINDNESS CANADA, August 2018, every year, around 1.4 million Canadians over age 50 experience vision loss due to age-related macular degeneration (AMD).
Competitive Landscape:
Key players operating in the North America & Europe age-related macular degeneration therapeutics market are Novartis AG, Bayer AG, Bausch Health Companies Inc., Regeneron Pharmaceuticals, Inc., F. Hoffmann-La Roche AG, Pfizer, Inc., and Valeant Pharmaceuticals International, Inc.
Buy-Now this Research Report @ https://www.coherentmarketinsights.com/insight/buy-now/4171
Market Segmentation:
-
North America & Europe Age-related Macular Degeneration Therapeutics Market, By Disease Type:
- Dry AMD
- Wet AMD
-
North America & Europe Age-related Macular Degeneration Therapeutics Market, By Drug Type:
- Aflibercept (Eylea)
- Ranibizumab (Lucentis)
- Bevacizumab (Avastin)
- Pegaptanib (Macugen)
- Verteporfin (Visudyne)
- Brolucizumab (Beovu)
- Supplements
- Others
-
North America & Europe Age-related Macular Degeneration Therapeutics Market, By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
-
North America & Europe Age-related Macular Degeneration Therapeutics Market, By Region:
-
North America
- U.S.
- Canada
-
Europe
- Germany
- U.K.
- France
- Italy
- Spain
- Russia
- Rest of Europe
-
North America
Related Market Intelligence Report:
Verteporfin Market, by Indication (Macular Degeneration, Pathological Myopia, and Ocular Histoplasmosis), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies and Online Pharmacies), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Size, Share, Outlook, and Opportunity Analysis, 2020 – 2027
Read more: https://www.coherentmarketinsights.com/ongoing-insight/verteporfin-market-4154
Eye Health Supplements Market, By Ingredient Type (Lutein and Zeaxanthin, Antioxidants, Omega-3 Fatty Acids, Coenzyme Q10, Flavonoids, Astaxanthin, Alpha-Lipoic Acid, Other Ingredients), By Indication Type (Age-related Macular Degeneration (AMD), Cataract, Dry Eye Syndrome, Other Indications), By Form (Tablet, Capsule, Others), and By Region (North America, Europe, Asia Pacific, Latin America, Middle East & Africa) - Size, Share, Outlook, and Opportunity Analysis, 2020 – 2027
Read more: https://www.coherentmarketinsights.com/market-insight/eye-health-supplements-market-3791
About Us:
Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having sales office at global financial capital in the U.S. and sales consultants in United Kingdom and Japan. Our client base includes players from across various business verticals in over 57 countries worldwide.
